Render Target: SSR
Render Timestamp: 2024-11-29T16:05:28.309Z
Commit: cd2fae6ca3f811b1ddb1df24ac291ed56d5d501b
XML generation date: 2024-08-01 15:30:41.979
Product last modified at: 2024-08-29T12:15:48.510Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

Phospho-RRM2 (Thr33) Antibody #74736

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 45
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Phospho-RRM2 (Thr33) Antibody recognizes endogenous levels of RRM2 protein only when phosphorylated at Thr33. By western blot, this antibody detects a 110 kDa band of unknown origin.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Thr33 of mouse RRM2 protein. Antibodies are purified by peptide affinity chromatography.

    Background

    Ribonucleotide reductase catalyzes the rate-limiting step in the synthesis of deoxynucleotide triphosphates (dNTPs). Ribonucleoside-diphosphate reductase subunit M2 (RRM2) is frequently overexpressed and associated with poor prognosis in multiple human cancers (1). RRM2/AKT/NF-κB signaling pathway is implicated in tumor invasiveness in gastric cancer (2). RRM2 is highly expressed in melanoma, and correlated with poor prognosis in BRAF-mutant melanoma. Knockdown of RRM2 stabilized the transient response of cells and patient-derived xenograft (PDX) model system to BRAF inhibition (3).
    Cyclin-dependent kinase (CDK) mediated phosphorylation of RRM2 at Thr33 targets the protein for degradation, allowing cells to maintain balanced dNTP pools (4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.